Thomson Reuters/Verus upgraded shares of Hi-Tech Pharmacal Co. (NASDAQ:HITK) from a hold rating to a buy rating in a report issued on Monday, Analyst Ratings.Net reports. Separately, analysts at Zacks upgraded shares of Hi-Tech Pharmacal Co. from an underperform rating to a neutral rating in a research note to investors on Tuesday, November 12th. They […]
Hi-Tech Pharmacal Co. Upgraded to “Buy” at Thomson Reuters/Verus (HITK) is a post from: Zolmax
The post Hi-Tech Pharmacal Co. Upgraded to “Buy” at Thomson Reuters/Verus (HITK) appeared first on Zolmax.